Autopsy report · NCT04386447

Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19

“The study was not approved by the Italian Medicines Agency (AIFA).”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Azienda Ospedaliero-Universitaria di Parma

Sponsor type

University, hospital or other

Conditions

Covid-19; Corona Virus Infection; SARS-CoV 2

Interventions

Oxytocin; Standard of Care

Participants

0

Sites

3

Countries

France, Italy

Trials that died the same way

• Iontophoresis in Psoriasis
  “FDA did not provide approval of the use of the drug for the study” (73% match in meaning)
• DASH - Decision Making in Adolescent Sexual Health
  “This research was not conducted at UNM \& not Applicable Clinical Trial.” (70% match in meaning)
• Coping Effectiveness Training for ALS
  “The study was not funded.” (69% match in meaning)
• Impact of Nutrition and Swallowing Function of Head and Neck Cancer Patients During the Course of Treatment
  “The study did not receive funding.” (68% match in meaning)
• A Coach-Guided Online Acceptance and Commitment Therapy (ACT) Intervention for Stroke Survivors
  “The research team decided not to implement this study.” (67% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.